Please login to the form below

Not currently logged in
Email:
Password:

Executive changes at Sanofi

Genzyme CEO Meeker becomes executive VP and Hellmann joins to lead animal health

David MeekerSanofi has added to its executive team with the appointments of Dr David Meeker and Carsten Hellmann.

Dr Meeker (pictured right) is currently CEO of Genzyme – the biotech acquired by Sanofi in 2011 – but from September 2013, he will serve on Sanofi's executive committee as executive VP, Genzyme.

Since the company's takeover, Dr Meeker has led the reorganisation of Genzyme, which has seen it establish itself as Sanofi's rare disease and multiple sclerosis business, with drugs such as Aubagio (teriflunomide) and Lemtrada (alemtuzumab).

“David has a deep knowledge of the rare diseases business and has developed a deep understanding of what physicians and patients need,” said Sanofi's CEO Christopher Viehbacher.

He added: “David will be a valuable addition to the Executive Committee and I am pleased to welcome him onboard.”

Carsten Hellmann, SanofiCarsten Hellmann (pictured left) joins Sanofi from food ingredient company Chr Hansen and takes over from Jose Barella as executive VP for Sanofi's animal health division Merial.

Hellmann was most recently executive VP, global sales at Chr Hansen having joined in 2006, and has previously served at Novo Nordisk and Synthelabo – one of the companies that merged to eventually become Sanofi.

He now takes control of a company with annual revenues of more than €2bn, making Merial the world's third-largest animal health company.

“I am confident that with [Hellmann's] expertise across the value chain from R&D, industrial affairs and through to business development and commercial sales, he will accelerate the growth of this promising division,” said Viehbacher.

1st August 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics